PARP1 and small cell lung carcinoma: The emerging immunomodulatory functions of DDR inhibitors have not been previously identified, but suggest that the combination of PARP or CHK1 inhibitors with immune checkpoint inhibitors may improve the therapeutic index in patients with SCLC.